Cognitive impairment in ‘non‐user’ first‐degree relatives of persons with cannabis dependence syndrome: A pilot, endophenotype study

AbstractIntroductionCannabis use disorders are global emerging problem nowadays, with high prevalence and morbidity. Cognitive impairments, and also corresponding genetic vulnerability, has been fairly replicated in individuals with cannabis dependence. However, there are few studies that assess cognitive functioning as an endophenotype or a trait marker for cannabis dependence. While the primary objective of this study was to assess the endophenotype pattern of cognitive dysfunction in cannabis dependence, assessing the association between the degree of cognitive functioning, and their socio‐demographic and clinical variables in the cannabis dependence patients and their first‐degree relatives was the secondary objective.MethodologyWe compared cognitive functioning across three groups‐ patients with cannabis dependence syndrome, their ‘non‐user’ first‐degree relatives and healthy controls, with 30 participants in each group. Five cognitive domains‐ attention and concentration, verbal fluency, memory, visuospatial ability and executive functions were assessed. We assessed for endophenotype pattern of statistical significance in pairwise analyses of Kruskal‐Wallis test, which was corrected for multiple comparisons. Subsequently, correlation analysis to assess association of cognitive impairment with socio‐demographic and clinical variables was conducted.ResultsAlthough impairment in attention and executive functions also was seen in patients with cannabis dependence, endophenotype pattern of statistical significance in pairwise analyses, with impairment in first‐degree relatives too, was seen in all sub‐scores of verbal fluency and verbal memory. None of the correlations were significant.Conclusion‘Non‐user’ first‐degree relatives of patients with cannabis dependence too show significant cognitive impairment. Verbal fluency and verbal memory are possible endophenotypes or trait markers for cannabis dependence syndrome.